ROCKVILLE, Md., March
9, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a
leading clinical-stage biotechnology company seeking to improve
lives through the curative potential of gene therapy based on its
proprietary NAV Technology Platform, today announced it will
present and hold a fireside chat at the Barclays Global Healthcare
Conference on Wednesday, March 11,
2020, at 2:35 p.m. ET. The
conference will be held in a virtual meeting format.
A live webcast of the presentation and fireside chat can be
accessed in the Investors section of REGENXBIO's website at
www.regenxbio.com. An archived replay of the webcast will be
available in the Investors section of REGENXBIO's website for
approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Heather Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-barclays-global-healthcare-conference-301019430.html
SOURCE REGENXBIO Inc.